Research Collaboration and License Agreement Sample Contracts
BY AND BETWEENResearch Collaboration and License Agreement • March 2nd, 2009 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Standard Contracts
RECITALSResearch Collaboration and License Agreement • May 1st, 2001 • Arqule Inc • Pharmaceutical preparations • Massachusetts
RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • September 13th, 2016 • AC Immune SA • Pharmaceutical preparations • New York
This Research Collaboration and License Agreement (“Agreement”) is made and entered into as of the 15th day of June 2012 (the “Effective Date”) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (“ACI”) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“GNE”) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). ACI and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.”
EX-10.17 21 d564688dex1017.htm EX-10.17 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between ARVINAS, INC. and...Research Collaboration and License Agreement • May 5th, 2020 • Delaware
This Agreement (this “Agreement”) is effective as of December 22, 2017 (the “Effective Date”), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (“Arvinas”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (“Pfizer”).
Exhibit 10.19 RESEARCH COLLABORATION AND LICENSE AGREEMENT This Research Collaboration And License Agreement (the "Agreement") is made by and between The R. W. Johnson Pharmaceutical Research Institute, a division of Ortho-McNeil Pharmaceutical, Inc.,...Research Collaboration and License Agreement • October 25th, 2000 • Dendreon Corp • Pharmaceutical preparations • California
RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN GILEAD SCIENCES, INC. AND HOOKIPA BIOTECH AGResearch Collaboration and License Agreement • March 19th, 2020 • HOOKIPA Pharma Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is made as of June 4, 2018 (the “Effective Date”), by and between Gilead Sciences, Inc., a Delaware corporation having an office at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”) and Hookipa Biotech AG, an Austrian corporation (Aktiengesellschaft) having an office at St Marx Vienna Bio Center: Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria (“Hookipa”). Gilead and Hookipa are each referred to individually as a “Party” and together as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • February 2nd, 2021 • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), effective as of the date this Agreement is duly executed by both Parties (the “Effective Date”), by and between ELI LILLY AND COMPANY, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”) and ABCELLERA BIOLOGICS INC., a corporation organized under the laws of British Columbia, Canada, with its principle business office located at 2215 Yukon St., Vancouver, BC V5Y 0A1, Canada (“AbCellera”). AbCellera and Lilly are each referred to individually as a “Party” and together as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND MACROGENICS, INC. OCTOBER 13, 2010Research Collaboration and License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of October 13, 2010 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, United States (“Pfizer”) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”). Pfizer and MacroGenics may each be referred to herein individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN DICERNA PHARMACEUTICALS, INC. AND KYOWA HAKKO KIRIN CO., LTD. December 21, 2009Research Collaboration and License Agreement • January 29th, 2014 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 21, 2009 ( the “Effective Date”), by and between DICERNA PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“DICERNA”), and KYOWA HAKKO KIRIN CO. LTD., a corporation organized and existing under the laws of Japan (“KHK”).
EX-10 6 filename6.htmResearch Collaboration and License Agreement • May 5th, 2020 • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
RESEARCH COLLABORATION AND LICENSE AGREEMENT between MERCK & CO., INC. and ARRIS PHARMACEUTICAL CORPORATIONResearch Collaboration and License Agreement • June 18th, 2008 • Celera CORP • Services-commercial physical & biological research • New Jersey
THIS AGREEMENT is effective as of November, 1996 (the “Effective Date”), between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey (“MERCK”) and ARRIS PHARMACEUTICAL CORPORATION, a corporation organized and existing under the laws of Delaware (“ARRIS”).
GW PHARMA LTD and OTSUKA PHARMACEUTICAL CO., LTD AMENDMENT NO.2 TO RESEARCH COLLABORATION AND LICENCE AGREEMENT DATED JULY 9, 2007Research Collaboration and License Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations • New York
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at **** (VAT ID number ****), effective as of June 4, 2009, as amended in the Amendment No. 1 dated June 7, 2011 (together the “Agreement”).
RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN METHYLGENE INC. AND OTSUKA PHARMACEUTICAL CO., LTD. DATED AS OF MARCH 25, 2008Research Collaboration and License Agreement • July 9th, 2013 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT is entered into this 25th day of March, 2008 (the “Effective Date”), by and between MethylGene Inc., a corporation organized under the laws of Quebec, Canada, having a business address at 7220 Frederick Banting, Montreal, QC H4S 2A1 (“MethylGene”), and Otsuka Pharmaceutical Co., Ltd., a company organized under the laws of Japan, having a business address at 2-9 Kanda-Tsukasamachi, Chiyoda-ku Tokyo 101-8535, Japan, acting through its Ophthalmology and Dermatology Division (“Otsuka”).
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 3 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment Agreement”), effective as of October 8, 2007, is entered into by and between Vitae Pharmaceuticals, Inc (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA. (taxpayer ID number 04-3567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at **** (VAT ID number ****). Vitae and BI may each be referred to as a “Party” or together as the “Parties.”
Research Collaboration and License AgreementResearch Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
EX-10.1 2 d778761dex101.htm EX-10.1 CONFIDENTIAL EXECUTION COPY *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION...Research Collaboration and License Agreement • May 5th, 2020 • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of March 14, 2014 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation have a place of business at 345 Park Avenue, New York, New York 10154 (“BMS”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at 2 Corporate Drive, South San Francisco, California 94080 (“FivePrime”). BMS and FivePrime are referred to individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License AgreementResearch Collaboration and License Agreement • April 29th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”)
THIRD AMENDMENT TO AGREEMENTResearch Collaboration and License Agreement • June 18th, 2008 • Celera CORP • Services-commercial physical & biological research
This is the third amendment to the Research Collaboration and License Agreement between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey (“MERCK”) and ARRIS PHARMACEUTICAL CORPORATION, a corporation organized and existing under the laws of Delaware, now known as Axys Pharmaceuticals, Inc. (“Axys”) made as of November 6, 1996 (the “Agreement”). The purpose of this third amendment is to extend the Research Program Term through November 5, 2000, and to [***].
EXHIBIT 10.119 THIRD AMENDMENT TO AGREEMENT This is the third amendment to the Research Collaboration and License Agreement between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey ("MERCK") and ARRIS PHARMACEUTICAL...Research Collaboration and License Agreement • March 8th, 2000 • Axys Pharmecueticals Inc • Pharmaceutical preparations
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 3 (“Amendment 3”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at ****(VAT ID number ****), effective as of June 4, 2009, as last amended by the Amendment No. 2 (“Amendment 2”) dated December 21, 2012 (together the “Agreement”).
RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND AMONG ADVANCED CARDIOVASCULAR DEVICES, INC. AND SOMANTA LIMITEDResearch Collaboration and License Agreement • February 6th, 2006 • Somanta Pharmaceuticals Inc. • Optical instruments & lenses • New York
RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • April 24th, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of December 28, 2017 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (“Sangamo”). Pfizer and Sangamo may each be referred to herein individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENT Between RAYZEBIO, INC. And NIMBLE THERAPEUTICS, INC.Research Collaboration and License Agreement • August 24th, 2023 • RayzeBio, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and License Agreement (the “Agreement”) is made and entered into as of February 8, 2021 (“Effective Date”) and is effective as of the Effective Date, between RayzeBio, Inc., a Delaware corporation having its principal place of business at 9880 Campus Point Dr., Suite 410, San Diego, CA 92121 (“Rayze”), and Nimble Therapeutics, Inc., a Delaware corporation having its principal place of business at 603 Science Dr., Madison, Wisconsin 53711 (“Nimble”). Rayze and Nimble are sometimes referred to individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: ****Research Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Agreement”) effective as of October 2, 2007 (“Effective Date”) is entered into by and between Vitae Pharmaceuticals, Inc (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA. (taxpayer ID number 04-3567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at **** (VAT ID number ****). Vitae and BI may each be referred to as a “Party” or together as the “Parties.”
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESEARCH COLLABORATION AND...Research Collaboration and License Agreement • September 9th, 2019 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of July 20, 2018 (the “Execution Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and BioNTech RNA Pharmaceuticals GmbH, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech RNA”) and BioNTech AG, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech AG”). BioNTech RNA and BioNTech AG are collectively referred to herein as “BioNTech”).Pfizer and BioNTech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and RBNC THERAPEUTICS, INC. Dated as of September 10, 2021Research Collaboration and License Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of September 10, 2021 (the “Execution Date”) is by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320, USA (“Amgen”) and RBNC Therapeutics, Inc., a Delaware corporation having an address at 1700 Owens Street, #535, San Francisco, California 94158, USA (“RBNC”). Amgen and RBNC are each hereafter referred to individually as a “Party” and together as the “Parties”.
AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases Research Program Expansion)Research Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This AMENDMENT NO. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 1”), effective as of the 17th day of May, 2011 (the “Amendment No. 1 Effective Date”), is made by and between GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”). GSK and FivePrime are referred to herein individually as a “Party” and collectively as the “Parties”.
EX-10.45 8 dex1045.htm RESEARCH COLLABORATION AND LICENSE AGREEMENT EXECUTION COPY CERTAIN MATERIAL (INDICATED BY AN ASTERISK [***]) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN...Research Collaboration and License Agreement • May 5th, 2020 • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is effective as of March 16, 2010 (the “Effective Date”), and is entered into by and between Prometheus Laboratories Inc., a California corporation (“Prometheus”), having its principal place of business at 9410 Carroll Park Drive, San Diego, CA 92121 USA, and Bayer Schering Pharma AG, a German corporation (“BSP”), having its principal place of business at 13342 Berlin, Germany. Prometheus and BSP may also individually be referred to herein as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • September 11th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (VAT ID number DE 811138149), effective as of June 4, 2009, as amended in the Amendment No. 1 dated June 7, 2011 (together the “Agreement”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • September 22nd, 2006 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made effective as of November 24, 2004 (“Effective Date”) by and between ACHILLION PHARMACEUTICALS, INC., a Delaware corporation (“Achillion”), with its principal place of business at 300 George Street, New Haven, Connecticut 06511, USA, and GILEAD SCIENCES, INC., a Delaware corporation (“Gilead”), with its principal place of business at 333 Lakeside Drive, Foster City, California 94404, USA. Achillion and Gilead are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
SEVENTH AMENDMENT TO AGREEMENTResearch Collaboration and License Agreement • June 18th, 2008 • Celera CORP • Services-commercial physical & biological research
This is the seventh amendment to the Research Collaboration and License Agreement between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey (“MERCK”) and ARRIS PHARMACEUTICAL CORPORATION, a corporation organized and existing under the laws of Delaware, now known as Axys Pharmaceuticals, Inc. (“Axys”) made as of November 6, 1996 (the “Agreement”). The purpose of this seventh amendment is to extend the Research Program Term through November 5, 2002, and to [***].
GW PHARMA LTD and OTSUKA PHARMACEUTICAL CO., LTD AMENDMENT NO.1 TO RESEARCH COLLABORATION AND LICENCE AGREEMENT DATED JULY 9, 2007Research Collaboration and License Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations • New York
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 2 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharamaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”) with offices at **** (VAT ID ****), effective as of October 2, 2007, as amended in the Amendment Agreement (deemed Amendment No. 1) dated October 8, 2007 (together “Agreement”).
